NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$20.30
-1.36 (-6.28%)
▼
5d:
-5.18%
30d:
-15.1%
90d:
-1.46%
HOLD
LOW Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 08, 2026
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NGNE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NGNE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $20.30, which is considered slightly low relative to its 30-day fair value range of $19.55 to $22.59.
Technical Outlook: Technically, NGNE is showing sideways momentum. Immediate support is located at $18.53, while resistance sits at $23.35. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.00 (+274.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NGNE is showing sideways momentum. Immediate support is located at $18.53, while resistance sits at $23.35. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (22th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.00 (+274.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$19.55 -
$22.59
Company Quality Score
51/100
(HOLD)
Options IV Signal
22th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 22th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 274.0% below Wall St target ($81.00)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$19.55 -
$22.59
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$3.35
(16.5%)
Support & Resistance Levels
Support Level
$18.53
Resistance Level
$23.35
Current Trend
Sideways
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.65
Wall Street Target
$81.00
(+274.0%)
Share & Embed Analysis
Last updated: April 02, 2026 2:25 PM ET
Data refreshes hourly during market hours. Next update: 3:25 PM
Data refreshes hourly during market hours. Next update: 3:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 58 HOLD |
